Post-authorisation study to evaluate the effectiveness of the risk minimisation activities in the treatment of SPAF (Risk minimisation in SPAF)

Study identification

• EU PAS number:
  EUPAS9111
• Study ID:
  12992
• Official title and acronym:
  Post-authorisation study to evaluate the effectiveness of the risk minimisation activities in the treatment of SPAF (Risk minimisation in SPAF)
• DARWIN EU® study:
  No
• Study countries:
  Bulgaria

  Czechia

  Denmark

  France

  Germany

  Slovakia

  Spain

  United Kingdom
• Study description:
  The objective of the investigation is evaluate the effectiveness of the risk minimisation activities in the treatment of stroke prevention in atrial fibrillation.
• Study status:
  Finalised

Research institutions and networks

Institutions

Multiple centres: 400 centres are involved in the study

Study timelines

Date when funding contract was signed

Planned:23/11/2012

Actual:25/06/2014

Study start date

Planned:01/10/2012

Actual:15/01/2015

Data analysis start date

Planned:01/10/2012

Actual:15/01/2015

Date of final study report

Planned:31/08/2015

Actual:12/02/2016

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim Pharma

Regulatory

• Was the study required by a regulatory body?:
  Yes